Baxter’s HyQvia Clears FDA With Label Warning On Antibody Development
Product is first subcutaneous immune globulin with once-monthly dosing regimen, but its safety had been a major concern of FDA and elicited a citizen petition.
Product is first subcutaneous immune globulin with once-monthly dosing regimen, but its safety had been a major concern of FDA and elicited a citizen petition.